Arm 1: Healthy Japanese Participants for Healthy Subjects

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Anaheim Clinical Trials LLC /ID# 252203, Anaheim, CAHealthy SubjectsABBV-552 - Drug
Eligibility
18 - 55
All Sexes
What conditions do you have?
Select

Study Summary

This trial will assess safety and how ABBV-552 moves through the body of 18 adult healthy Japanese & Han Chinese volunteers. Adverse Events will be monitored.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

11 Primary · 0 Secondary · Reporting Duration: Up to approximately 45 days

Day 21
AUC From Time Zero to Infinite Time (AUCinf) of ABBV-552
AUC of ABBV-552 (Arm 1)
Apparent Oral Clearance (CL/F) of ABBV-552
Apparent Volume of Distribution (Vz/F) of ABBV-552
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Measurable Concentration (AUCt) of ABBV-552
Dose-Normalized Cmax of ABBV-552 (Arm 1)
Maximum Observed Plasma Concentration (Cmax) of ABBV-552
Terminal Phase Elimination Half-Life (t1/2) of ABBV-552
Terminal Phase Elimination Rate Constant (λz) of ABBV-552
Time to Cmax (Tmax) of ABBV-552
Day 45
Number of Participants With Adverse Events (AE)

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Arm 1: Healthy Japanese Participants
1 of 2
Arm 2: Healthy Han Chinese Participants
1 of 2

Experimental Treatment

18 Total Participants · 2 Treatment Groups

Primary Treatment: Arm 1: Healthy Japanese Participants · No Placebo Group · Phase 1

Arm 1: Healthy Japanese Participants
Drug
Experimental Group · 1 Intervention: ABBV-552 · Intervention Types: Drug
Arm 2: Healthy Han Chinese Participants
Drug
Experimental Group · 1 Intervention: ABBV-552 · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 45 days

Who is running the clinical trial?

AbbVieLead Sponsor
849 Previous Clinical Trials
473,168 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
312 Previous Clinical Trials
120,622 Total Patients Enrolled

Eligibility Criteria

Age 18 - 55 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Has the arm of this study involving healthy Japanese individuals been approved by the FDA?

"The safety of Arm 1: Healthy Japanese Participants is estimated at a score of 1 due to the lack of data regarding efficacy and safety, as this is an experimental Phase one trial." - Anonymous Online Contributor

Unverified Answer

Who qualifies for enrollment in this medical experiment?

"Qualifying individuals should be healthy adults in the 18 to 55 age range, and this study aims to recruit roughly 18 participants." - Anonymous Online Contributor

Unverified Answer

Are participants at least 85 years of age eligible for this exploration?

"Eligible participants in this medical study must be between 18 and 55 years old." - Anonymous Online Contributor

Unverified Answer

Does this research currently have open enrollment?

"This clinical trial, which was initially shared on January 17th 2023 and recently updated on the 13th of this month, is actively looking for participants. This information can be found on clinicaltrials.gov." - Anonymous Online Contributor

Unverified Answer

What is the total enrollment of this research project?

"That is correct. According to the clinicaltrials.gov platform, this medical investigation has been recruiting since January 17th 2023 and was last updated on January 13th 2023. Currently, 18 participants are needed across two distinct research centres." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.